

INFORMATION  
ANALYSIS  
DIRECTORATE



# Investment in General Practice, Northern Ireland 2017-18 to 2021-22



Department of  
**Health**

An Roinn Sláinte

Máinnystrie O Poustie

[www.health-ni.gov.uk](http://www.health-ni.gov.uk)

## **Investment in General Practice, Northern Ireland 2017-18 to 2021-22**

**Publication Date: 7 October 2022**

### **Introduction:**

This report details the investment in general practice and the reimbursement for drugs dispensed in general practices in Northern Ireland from 2017-18 to 2021-22. The report draws on information from the financial reporting system of the Health and Social Care Board (HSCB)<sup>1</sup> and other published data on reimbursement and remuneration for dispensing activity derived from the Family Practitioner Services Pharmacy Payments System maintained by the Business Services Organisation (BSO).

The data also contain some financial flows which do not reach GP Practices, but contribute towards overall General Medical Services (GMS) investment. These include payments for Information Management and Technology (IM&T) and out-of-hours services.

The figures include expenditure relating to dispensing by GP practices, but not the costs of drugs dispensed by high street pharmacies. The total cost of all prescriptions dispensed in the community by community pharmacists, appliance contractors and dispensing doctors, can be found in the Prescription Cost Analysis produced by the Business Services Organisation (BSO). This can be found on the BSO's website at:

<http://www.hscbusiness.hscni.net/services/3177.htm>

### **Discontinued NHS Digital Publication:**

Previously country level information from all 4 UK countries was discussed by the Technical Steering Committee (TSC), which is chaired by NHS Digital and has representation from the Department of Health and Social Care, UK Health Departments, NHS England and NHS Improvement, NHS Employers and the British Medical Association (BMA). Since 2003-04, NHS Digital have provided a rolling five-year time series of Investment in General Practice for each UK country. As well as providing UK-level figures, the report was intended to facilitate comparison of spending across the countries.

However, changes to general practice contractual arrangements in each country over recent years mean the payment categories and spending practices are no longer comparable. As a result, the Technical Steering Committee, which oversaw this series, decided that this UK-level report was no longer relevant or appropriate and have discontinued the series. This can be found at: <http://www.digital.nhs.uk>

From 2020, each country agreed to produce and publish its own report, with NHS Digital providing links to these reports once released. It is important to note that figures between these individual country reports will not be comparable due to the differing contractual arrangements which have led to the UK-level report being discontinued.

<sup>1</sup> The HSCB officially closed on 31 March 2022; responsibility for its functions transferred to the Department of Health (DoH). This latest release refers to data up to financial year 2021-22 when the HSCB was still in operation.

## Contents:

Contents	Description	Page Number
<b>Table 1</b>	Investment in General Practice in Northern Ireland, 2017-18 to 2021-22 (excluding reimbursement of drugs)	5
<b>Table 2</b>	Total Investment in General Practice in Northern Ireland, 2017-18 to 2021-22	5
<b>Figure 1</b>	Investment in General Practice in Northern Ireland, 2017-18 to 2021-22	6
<b>Figure 2</b>	Total Investment in General Practice in Northern Ireland, 2009-10 to 2021-22 (cash and real terms)	6
<b>Table 3a</b>	5-Year Trend Summary Table	7
<b>Table 3b</b>	Detailed Table 2021-22	8
<b>Table 3c</b>	Supplementary Information 2021-22	9
<b>Other Publications</b>		10

## Key Facts:

In 2021-22, the total investment in general practice, including the reimbursement of drugs dispensed in general practice, was £377.874m. This represents an increase in the total investment in GP practices of 2.85 per cent in Northern Ireland. In real terms this equates to an increase of 3.07 per cent.

In 2021-22, in response to the recommendation in the report of the Review Body on Doctors' and Dentists' Remuneration (DDRB), a 3.0% uplift was applied for GP pay and practice staff expenses and a 2.4% uplift for other expenses. This represents an investment of £7.114m.

For 2021-22, the value of a Quality and Outcomes Framework point remained at £178.25.

## Data Quality:

Assessment of the quality of the statistics and the data sources is provided in a separate document available on the publication page at:

<https://www.health-ni.gov.uk/articles/investment-general-practice>

## Further Information:

Details of other publications of interest can be found at the end of this report.

**For further information, contact:**

Information & Analysis Directorate,  
Department of Health,  
Room 2,  
Annex 2, Castle Buildings,  
Stormont Estate,  
Belfast,  
BT4 3SQ

**Responsible Statistician:** Penny Murray

**Telephone:** 028 9052 2700

**E-mail:** [gofdataenquiries@health-ni.gov.uk](mailto:gofdataenquiries@health-ni.gov.uk)

**Feedback:** We welcome feedback on any aspects of these statistics. This can be provided at the e-mail address above.

**Table 1: Investment in General Practice in Northern Ireland 2017-18 to 2021-22 (excluding reimbursement of drugs)**

£ Millions

	2017-18	2018-19	2019-20	2020-21 <sup>#</sup>	2021-22 <sup>#</sup>
Cash Terms	£280.237	£299.174	£322.268	£363.682	£374.244
% Change	:	6.76%	7.72%	12.85%	2.90%
Real Terms	£308.012	£322.531	£339.712	£362.879	£374.244
% Change	:	4.71%	5.33%	6.82%	3.13%

**Source: Financial Information Monitoring Returns (HSCB); year ended March 2018 to 2022**

<sup>#</sup>Funding in relation to the covid 19 response commenced in 2020-21 and remained for 2021-22, stabilising in 2021-22; this funding is reported under Local Enhanced Services.

Note: Further information on how the Real Terms figures have been calculated using the GDP deflator can be found at:

<https://www.gov.uk/government/publications/gross-domestic-product-gdp-deflators-user-guide>

<https://www.gov.uk/government/statistics/gdp-deflators-at-market-prices-and-money-gdp-june-2022-quarterly-national-accounts>

Real terms figures have been based on unrounded figures.

**Table 2: Total Investment in General Practice in Northern Ireland 2017-18 to 2021-22**

£ Millions

	2017-18	2018-19	2019-20	2020-21 <sup>#</sup>	2021-22 <sup>#</sup>
Cash Terms	£284.101	£303.207	£326.507	£367.416	£377.874
% Change	:	6.72%	7.68%	12.53%	2.85%
Real Terms	£312.259	£326.878	£344.180	£366.605	£377.874
% Change	:	4.68%	5.29%	6.52%	3.07%

**Source: Financial Information Monitoring Returns (HSCB); year ended March 2018 to 2022 Family Practitioner Services Pharmacy Payments System, BSO**

<sup>#</sup>Funding in relation to the covid 19 response commenced in 2020-21 and remained for 2021-22, stabilising in 2021-22; this funding is reported under Local Enhanced Services.


Note: Further information on how the Real Terms figures have been calculated using the GDP deflator can be found at:

<https://www.gov.uk/government/publications/gross-domestic-product-gdp-deflators-user-guide>

<https://www.gov.uk/government/statistics/gdp-deflators-at-market-prices-and-money-gdp-june-2022-quarterly-national-accounts>


Real terms figures have been based on unrounded figures.

**Figure 1: Investment in General Practice in Northern Ireland, 2017-18 to 2021-22**



**Source:** Financial Information Monitoring Returns (HSCB); year ended March 2018 to 2022  
Family Practitioner Services Pharmacy Payments System, BSO

**Figure 2: Investment in General Practice in NI - Total Investment, 2009-10 to 2021-22, £m, Cash and Real Terms\***



\* Real terms represents the cash terms adjusted to 2021-22 practices using GDP deflators at June 2022

**Source:** Financial Information Monitoring Returns (HSCB); year ended March 2018 to 2022  
Family Practitioner Services Pharmacy Payments System, BSO

**Note:** Data prior to 2009-10 is not comparable due to a change in methodology for deriving dispensing figures. This new methodology was adopted in 2013-14 and figures were revised back to 2009-10.

**Table 3a: 5-Year Trend Summary Table**

£ thousands

	2017-18	2018-19	2019-20	2020-21	2021-22
<b>Global Sum/MPIG</b>	<b>146,031</b>	<b>153,680</b>	<b>169,940</b>	<b>176,372</b>	<b>185,081</b>
<b>Quality and Outcomes Framework</b>	<b>30,074</b>	<b>30,738</b>	<b>31,014</b>	<b>31,645</b>	<b>31,605</b>
Direct Enhanced Services	13,375	13,654	13,433	14,814	13,162
Local Enhanced Services <sup>1</sup>	4,618	8,262	11,155	37,148	34,202
Regional Enhanced Services (including Clinical Priorities)	22,462	26,981	29,590	35,749	41,093
<b>Total Enhanced Services<sup>2</sup></b>	<b>40,456</b>	<b>48,898</b>	<b>54,178</b>	<b>87,712</b>	<b>88,457</b>
Premises	16,649	18,247	18,871	18,370	22,720
HSCB Administered Funds/Other GMS Services <sup>3</sup>	14,641	15,176	16,609	18,503	15,040
Out of Hours (including OOH Development Fund)	27,616	27,307	26,388	25,928	26,205
IM and IT	4,633	4,995	5,125	5,020	4,995
<b>Total Other Payments</b>	<b>63,539</b>	<b>65,725</b>	<b>66,992</b>	<b>67,821</b>	<b>68,960</b>
<b>Subtotal</b>	<b>280,100</b>	<b>299,041</b>	<b>322,124</b>	<b>363,550</b>	<b>374,104</b>
<b>Total Net of Dispensing</b>	<b>280,100</b>	<b>299,041</b>	<b>322,124</b>	<b>363,550</b>	<b>374,104</b>
Cost of Dispensing Fees <sup>4</sup>	137	133	144	132	140
<b>Total Investment Excluding Reimbursement of Drugs<sup>5</sup></b>	<b>280,237</b>	<b>299,174</b>	<b>322,268</b>	<b>363,682</b>	<b>374,244</b>
Reimbursement of Dispensed Drugs <sup>6</sup>	3,864	4,033 <sup>7</sup>	4,239	3,734	3,630
<b>Total Spend<sup>8</sup></b>	<b>284,101</b>	<b>303,207</b>	<b>326,507</b>	<b>367,416</b>	<b>377,874</b>

**Source: Financial Information Monitoring Returns (HSCB); year ended March 2018 to 2022 Family Practitioner Services Pharmacy Payments System, BSO**

1. 2020-21 and 2021-22 include funding in relation to Covid 19 response.
2. There are no National Enhanced Services in place in Northern Ireland.
3. Dispensing element of HSCB administered funds reported on separate line.
4. This figure refers only to the cost of dispensing fees for items dispensed and/or personally administered by dispensing doctors.
5. This total includes the cost of dispensing fees but not reimbursement of the cost of drugs.
6. This total includes Net Ingredient Cost (NIC), vat allowance and discounts and stock order costs (NIC) for both dispensing doctors and non-dispensing doctors.
7. Figure has been revised since previously published in Investment in General Practice 2014-15 to 2018-19; England, Wales, Northern Ireland and Scotland (NHS Digital).
8. Figures may not sum to total due to rounding.

**Table 3b: Detailed Table 2021-22**

£ thousands

Global Sum	177,206
MPIG Correction Factor	7,875
<b>Total Global Sum and MPIG</b>	<b>185,081</b>
Quality Aspiration Payments	21,913
Quality Achievement Payments	9,692
<b>Total Quality and Outcomes Framework</b>	<b>31,605</b>
Direct Enhanced Services	13,162
Local Enhanced Services <sup>1</sup>	34,202
Regional Enhanced Services (including Clinical Priorities)	41,093
<b>Total Enhanced Services<sup>2</sup></b>	<b>88,457</b>
Premises	22,720
HSCB Administered Funds/Other GMS Services <sup>3</sup>	15,040
Out of Hours	26,205
IM and IT	4,995
<b>Total Other Payments</b>	<b>68,960</b>
<b>Subtotal</b>	<b>374,104</b>
<b>Total Net of Dispensing</b>	<b>374,104</b>
Cost of Dispensing Fees <sup>4</sup>	140
<b>Total Investment Excluding Reimbursement of Drugs<sup>5</sup></b>	<b>374,244</b>
Reimbursement of Dispensed Drugs <sup>6</sup>	3,630
<b>Total Spend<sup>7</sup></b>	<b>377,874</b>

**Source: Financial Information Monitoring Returns; year ended March 2022  
Family Practitioner Services Pharmacy Payments System, BSO**

1. Includes funding in relation to Covid 19 response.
2. There are no National Enhanced Services in place in Northern Ireland.
3. Dispensing element of HSCB administered funds reported on separate line.
4. This figure refers only to the cost of dispensing fees for items dispensed and/or personally administered by dispensing doctors.
5. This total includes the cost of dispensing fees but not reimbursement of the cost of drugs.
6. This total includes Net Ingredient Cost (NIC), vat allowance and discounts and stock order costs (NIC) for both dispensing doctors and non-dispensing doctors.
7. Figures may not sum to total due to rounding.



**Table 3c: Supplementary Information 2021-22**

£ thousands

<b>Direct Enhanced Services</b>	
Childhood Vaccination and Immunisation Scheme	4,612
Influenza and Pneumococcal Immunisations Scheme	3,966
Learning Disabilities	927
MEN ACWY	16
Minor Surgery	3,293
Services for Violent Patients	252
Shingles Vaccinations	97
<b>Total Direct Enhanced Services<sup>1</sup></b>	<b>13,162</b>
<b>HSCB Administered Funds/Other Services</b>	
Seniority	5,801
Doctors Retainer Scheme Payments/NI GP Development Scheme	0
Locum Allowances consisting of:	
a) Adoptive, paternity and maternity	1,134
b) Sickness	823
c) Suspended Doctors	0
d) Other Locum payments	0
Appraiser Costs of Sessional GPs	148
Practice Training	175
Interpreting	110
Treatment Room Nursing	2,777
GP Locum Superannuation	971
GP Consumables reimbursement scheme	635
GP Federation Infrastructure Costs	0
Medical Equipment and Data Storage	877
Miscellaneous	1,590
<b>Total HSCB Administered Funds/Other Services<sup>1</sup></b>	<b>15,040</b>

**Source: Financial Information Monitoring Returns; year ended March 2022**

1. Figures may not sum to total due to rounding.

## Other Publications:

### Investment in General Practice in England, 2016/17 to 2020/21

Current Link: <https://www.england.nhs.uk/publication/investment-in-general-practice-in-england-2016-17-to-2020-21/>

Summary: This report details the investment in General Practice and the reimbursement for drugs dispensed in General Practices in England from 2016/17 to 2020/21. The report draws on information from the financial reporting systems of NHS England and Improvement and other published data on reimbursement and remuneration for dispensing activity. This information has been discussed with the General Practitioners Committee (GPC) of the British Medical Association (BMA), which represents the interests of GPs.

Previous Versions: This is the second year of this publication.

<https://www.england.nhs.uk/publication/investment-in-general-practice-in-england-2015-16-to-2019-20/>

Previously NHS Digital published country level information for all 4 UK countries, see below.

### Investment in General Practice in Wales, 2016/17 to 2020/21

Current Link: <https://gov.wales/investment-general-practice-wales-2016-2017-financial-year-2020-2021-financial-year>

Summary: This report details the investment in General Practice and the reimbursement for drugs dispensed in General Practices in Wales from 2016/17 to 2020/21.

Previous Versions: This is the second year of this publication.

Previously NHS Digital published country level information for all 4 UK countries, see below.

## **Investment in General Practice 2014/15 to 2018/19; England, Wales, Northern Ireland and Scotland**

Current Link: <https://digital.nhs.uk/data-and-information/publications/statistical/investment-in-general-practice/2014-15-to-2018-19-england-wales-northern-ireland-and-scotland>

Summary: This report details the investment in General Practice and the reimbursement for drugs dispensed in General Practices from 2014/15 to 2018/19. The report draws on information from country level financial monitoring reports discussed by the Technical Steering Committee (TSC). This series has been discontinued.

Previous Versions: <http://www.digital.nhs.uk>

## **2020-21 GP Earnings and Expenses Report**

Current Link: <https://digital.nhs.uk/data-and-information/publications/statistical/gp-earnings-and-expenses-estimates/2020-21>

Summary: This report presents results from the GP Earnings and Expenses Enquiry for the financial year 2020-21.

Previous Versions: <http://www.digital.nhs.uk>

## **The Quality and Outcomes Framework 2020-21 for Northern Ireland**

Current Link: <https://www.health-ni.gov.uk/articles/quality-and-outcomes-framework-qof-statistics-annual-report>

Summary: This statistical publication presents a summary of data (achievement and exceptions data) from the Quality and Outcomes Framework (QOF). The QOF was first implemented in general practices in April 2004. Information is derived from the Payment Calculation and Analysis System (PCAS), a NI system that uses data from NI general practices to calculate QOF achievement for individual practices.

Previous Versions: <https://www.health-ni.gov.uk/publications/quality-and-outcomes-framework-qof-achievement-exception-reporting-statistics-2015-16-2019-20>

## **Disease Prevalence Data for Northern Ireland**

Current Link: <https://www.health-ni.gov.uk/articles/prevalence-statistics>

Summary: This bulletin presents raw disease prevalence data at GP Federation, LCG and Northern Ireland levels. Time series data is presented for Northern Ireland, with LCG and GP federation data given for the current year, for each of the 15 registers which count patients with specific conditions or diseases as covered by the Quality and Outcomes Framework. A comprehensive excel spreadsheet, which also includes GP practice level data, and an interactive tool accompany the bulletin.

Previous Versions: <https://www.health-ni.gov.uk/publications/200405-202021-raw-disease-prevalence-data-northern-ireland>

## **General Medical Services Statistics**

Current Link: <http://www.hscbusiness.hscni.net/services/3174.htm>

Summary: The Family Practitioner Services (FPS) Information Unit of the Business Services Organisation (BSO) produces information on General Practitioners, GP practices and registered patients including registration activity and payments.

Previous Versions: <http://www.hscbusiness.hscni.net/services/3181.htm>